Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;55(10):1709-1720.
doi: 10.1038/s41588-023-01515-7. Epub 2023 Sep 25.

Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities

Affiliations

Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities

Liang Chang et al. Nat Genet. 2023 Oct.

Erratum in

Abstract

The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer. Conversely, conditional activation of signaling pathways as a new source of selective cancer vulnerabilities has not been deeply characterized. In this study, we sought to systematically identify context-specific gene-activation-induced lethalities in cancer. To this end, we developed a method for gain-of-function genetic perturbations simultaneously across ~500 barcoded cancer cell lines. Using this approach, we queried the pan-cancer vulnerability landscape upon activating ten key pathway nodes, revealing selective activation dependencies of MAPK and PI3K pathways associated with specific biomarkers. Notably, we discovered new pathway hyperactivation dependencies in subsets of APC-mutant colorectal cancers where further activation of the WNT pathway by APC knockdown or direct β-catenin overexpression led to robust antitumor effects in xenograft and patient-derived organoid models. Together, this study reveals a new class of conditional gene-activation dependencies in cancer.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Chang, L., Ruiz, P., Ito, T. & Sellers, W. R. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell 39, 466–479 (2021). - PubMed - PMC - DOI
    1. Mauro, M. J. & Druker, B. J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 6, 233–238 (2001). - PubMed - DOI
    1. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science 304, 1497–1500 (2004). - PubMed - DOI
    1. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012). - PubMed - PMC - DOI
    1. Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019). - PubMed - DOI

Substances